Physiological properties of enkephalin-containing neurons in the spinal dorsal horn visualized by expression of green fluorescent protein in BAC transgenic mice by Fukushima, Teruyuki et al.
RESEARCH ARTICLE Open Access
Physiological properties of enkephalin-containing
neurons in the spinal dorsal horn visualized by





2 and Yuuichi Hori
1
Abstract
Background: Enkephalins are endogenous opiates that are assumed to modulate nociceptive information by
mediating synaptic transmission in the central nervous system, including the spinal dorsal horn.
Results: To develop a new tool for the identification of in vitro enkephalinergic neurons and to analyze enkephalin
promoter activity, we generated transgenic mice for a bacterial artificial chromosome (BAC). Enkephalinergic
neurons from these mice expressed enhanced green fluorescent protein (eGFP) under the control of the
preproenkephalin (PPE) gene (penk1) promoter. eGFP-positive neurons were distributed throughout the gray matter
of the spinal cord, and were primarily observed in laminae I-II and V-VII, in a pattern similar to the distribution
pattern of enkephalin-containing neurons. Double immunostaining analysis using anti-enkephalin and anti-eGFP
antibodies showed that all eGFP-expressing neurons contained enkephalin. Incubation in the presence of forskolin,
an activator of adenylate cyclase, increased the number of eGFP-positive neurons. These results indicate that eGFP
expression is controlled by the penk1 promoter, which contains cyclic AMP-responsive elements. Sections obtained
from sciatic nerve-ligated mice exhibited increased eGFP-positive neurons on the ipsilateral (nerve-ligated side)
compared with the contralateral (non-ligated side). These data indicate that PPE expression is affected by
peripheral nerve injury. Additionally, single-neuron RT-PCR analysis showed that several eGFP positive-neurons in
laminae I-II expressed glutamate decarboxylase 67 mRNA and that some expressed serotonin type 3 receptors.
Conclusions: These results suggest that eGFP-positive neurons in laminae I-II coexpress enkephalin and g-
aminobutyric acid (GABA), and are activated by forskolin and in conditions of nerve injury. The penk1-eGFP BAC
transgenic mouse contributes to the further characterization of enkephalinergic neurons in the transmission and
modulation of nociceptive information.
Background
Enkephalin-containing neurons are found in several
areas of the central nervous system, including the dorsal
horn of the spinal cord [1-3], where they play an impor-
tant role in the transmission and modulation of nocicep-
tive information [4].
The analgesic effect of intrathecally administered 5-
hydroxytryptamine (5-HT) type 3 (5-HT3) receptor
agonist 2-methyl-serotonin is attenuated by the opioid
antagonist naloxone [5,6], suggesting that endogenous
opiate-like substances may be involved in 5-HT-induced
antinociception. Enkephalin-containing neurons in the
superficial dorsal horn (SDH) of the spinal trigeminal
nucleus in rats are innervated by 5-HT-containing fibers
[7-9]. Furthermore, we have reported that enkephaliner-
gic neurons express 5-HT3 receptors in the dorsal horn
of the spinal cord [10]. These findings suggest that
some antinociception is elicited by activation of 5-HT3
receptors in spinal dorsal horn neurons containing
enkephalin.
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eral SDH neurons contain both enkephalin and g-ami-
nobutyric acid (GABA) [11-13]. We showed that
activation of 5-HT3 receptors facilitates the release of
GABA from some interneurons in SDH [14]. Thus, the
antinociceptive action of 5-HT may depend on the
release of both enkephalin and GABA by SDH inter-
neurons that express 5-HT3 receptors.
The preproenkephalin (PPE) promoter contains cyclic
AMP (cAMP)-responsive elements, and the expression
of enkephalin is controlled by cAMP [15]. We observed
that forskolin, an activator of adenylate cyclase (AC),
affects the expression of enkephalin-green fluorescent
protein (GFP) fluorescence in neurons in mouse spinal
cord sections transfected with the GFP gene driven by
the PPE promoter [16].
Peripheral nerve injury and tissue inflammation often
induce a state of abnormal pain known as neuropathic
pain, which includes hyperalgesia and allodynia [17].
Chronic constriction injury (CCI) of the sciatic nerve
increases Met-enkephalin immunoreactivity in the spinal
cord [18]. Increases in enkephalin have also been
described in spinal cord injury [19], polyarthritis [20],
electrical stimulation [21], and various other prepara-
tions, using immunocytochemistry and in situ hybridiza-
tion histochemistry to detect changes in enkephalin. To
develop a new, more efficient, tool for the analysis of
enkephalin promoter activity and characterization of
enkephalinergic neurons, we generated a bacterial artifi-
cial chromosome (BAC) transgenic mouse in which
enhanced green fluorescent protein (eGFP) is expressed
in enkephalinergic neurons under the control of the
PPE gene (penk1) promoter.
Results
eGFP expression and endogenous enkephalin expression
Figure 1A shows an overview of the distribution of
eGFP-positive neurons in the lumbar spinal cord, show-
ing a dense distribution of eGFP-positive neurons in
SDH and infrequent eGFP-positive neurons sparsely dis-
tributed throughout the deep dorsal horn and central
canal. The observed distribution of eGFP-positive neu-
rons is similar to that of a previous report demonstrat-
ing that many interneuronal somata in the substantia
gelatinosa show enkephalin immunoreactivity [3,8,22].
To assess the correlation of eGFP fluorescence with
endogenous enkephalin expression in SDH, we per-
formed double immunostaining with anti-eGFP and
anti-enkephalin antibodies. Figure 1(B-D) shows repre-
sentative double-staining immunohistochemical images
for eGFP and enkephalin. In 26 sections randomly
selected from three mice, we determined that, of the
1550 lamina II neurons immunostained for eGFP, 1544
(99.6%) were also immunolabeled for enkephalin. In the
same 26 sections, 1552 lamina II neurons were immu-
nostained for enkephalin, and 1544 (99.5%) were immu-
nolabeled for eGFP.
Increased number of eGFP-positive neurons in the
presence of forskolin
The expression of enkephalin is controlled by cAMP,
owing to the cAMP-responsive elements contained
within the PPE promoter [23]. We examined whether
our penk1-eGFP BAC transgenic mouse was useful for
analyzing the effect of forskolin, an activator of AC, on
the PPE promoter. To evaluate the effect of forskolin
treatment, transverse spinal sections were exposed to a
60 minutes bath application of forskolin, and the num-
ber of eGFP-positive neurons was counted at 5-minute
intervals. The number of eGFP-positive neurons in sec-
tions significantly increased compared to the control
when forskolin was added to the Krebs solution, while
the number of control (without forskolin treatment)
decreased gradually with fading of eGFP fluorescence
upon exposure to ultraviolet (UV) light, as illustrated in
Figure 2C. The effect of forskolin was statistically signifi-
cant (ANOVA, P < 0.05; Figure 2C) in a comparison
between forskolin treatment (n = 7) and the control (n
= 7). Percentage increase in the ratio of the number of
eGFP-positive neurons with forskolin treatment to the
number of control neurons was 21.8% ± 7.5% after 1 h
of forskolin treatment (filled square in Figure 2C). This
increase in eGFP-positive neurons may reflect an
increase in the expression level of enkephalin above the
detection threshold in neurons with relatively low basal
enkephalin levels or alternatively, de novo enkephalin
expression in neuron populations.
Increased number of eGFP-positive neurons in partial
sciatic nerve ligations
Met-enkephalin immunoreactivity in the spinal cord
dorsal horn increases after sciatic nerve ligation [18]. To
confirm whether our BAC transgenic mouse is useful
for analyzing the effect of sciatic nerve ligation on enke-
phalin expression, the number of eGFP-positive neurons
on the sciatic nerve-ligated (ipsilateral) side was com-
pared with the number on the nonligated (contralateral)
side in spinal sections. The number of eGFP-positive
neurons significantly increased in ipsilateral compared
with contralateral [ipsilateral, 66.06 ± 2.42 (n = 18); con-
tralateral, 58.00 ± 1.55 (n = 18); P < 0.01; Figure 3]. This
result is consistent with a previous report [18].
Reverse-transcription polymerase chain reaction (RT-PCR)
analysis of the expression of glutamate decarboxylase 67
and 5-HT3 receptor mRNAs in eGFP-positive neurons
PCR products of glutamate decarboxylase 67 (GAD67)
and 5-HT3 receptor were detected in eGFP-positive
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RT-PCR indicated that GAD67 (detected in 15/15
eGFP-positive neurons, 100.0%) and 5-HT3 receptors
(detected in 6/27 eGFP-positive neurons, 22.2%) were
co-expressed in the somatodendritic regions of the
enkephalinergic neurons in SDH.
Discussion
Distribution of enkephalinergic neurons in SDH
We visualized presumptive enkephalinergic neurons in
the spinal cord sections by generating a BAC transgenic
mouse in which eGFP is expressed in enkephalinergic
neurons under the control of the penk1 promoter.
Immunohistochemical investigations showed that enke-
phalinergic neurons were located in the dorsal horn of
the spinal cord, with the highest density in the superfi-
cial laminae, thus suggesting eGFP-positive neurons are
enkephalinergic. This distribution in the mouse model is
similar to that described previously in rat and cat mod-
els [3,8].
Co-expression of enkephalin, GAD67, and 5-HT3 receptor
mRNAs in interneurons in SDH
Single-neuron RT-PCR analysis showed that most eGFP-
positive neurons expressed GAD67 mRNAs and that
some expressed 5-HT3 receptor mRNAs. We previously
Figure 1 Distribution of eGFP-positive neurons and double-staining IHC colocalization of eGFP expression with endogenous
enkephalin. (A) Low magnification of the L4 segment of the spinal cord shows the highest density of eGFP-positive somata and fibers in SDH.
(B)-(D) Identification of eGFP-expressing neurons as enkephalinergic by double-staining IHC analysis with anti-eGFP (B, green) and anti-enkephalin
(C, red) in SDH of penk1-eGFP BAC transgenic mouse. Scale bar = 200 μm in (A), 20 μm in (B)-(D).
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receptors in SDH [10] and that activation of 5-HT3
receptors facilitates GABA release from some interneur-
o n si nS D H[ 1 4 ] .T h e s er e s u l t ss u p p o r tt h eh y p o t h e s i s
that the release of enkephalin or the release of both
enkephalin and GABA from some eGFP-positive neu-
rons is facilitated by activation of 5-HT3 receptors.
Changes in enkephalin expression induced by various
treatments as models of chronic pain in the spinal cord
Analyses of the expression of enkephalin in the spinal
cord during chronic inflammation have been previously
reported in a number of models. Increases in PPE
mRNA-labeled neurons in SDH have been reported in a
number of injury model studies, including intraspinal
microinjection of quisqualic acid to induce excitotoxic
spinal cord injury [19], intraplantar injection of lambda
Figure 2 Effect of forskolin on the number of eGFP-positive neurons. (A, B) Representative images of eGFP fluorescence in the dorsal horn
before (A) and after (B) treatment with forskolin. (C) Forskolin (5 μM) was applied as indicated by the horizontal bar. Data points on the graph
(open circles and filled circles) indicate percentage of the number of eGFP-positive neurons normalized to the first ones at 10 minutes before
forskolin treatment. Open circles and filled circles indicate the mean percentage of the number of eGFP-positive neurons with forskolin
treatment (n = 7) and control neurons (n = 7), respectively. Filled squares indicate percent increases in the ratio of the number of eGFP-positive
neurons with forskolin treatment to the number of control neurons. *P < 0.05 indicates a significant difference between the forskolin treatment
and the control neurons.
Figure 3 Sciatic nerve ligation increased the number of eGFP-
positive neurons. (A) Representative image of eGFP fluorescence in
SDH. eGFP fluorescence intensity was higher on the side ipsilateral
(the right side of the figure) to sciatic nerve ligation 2 weeks after
surgery compared with the contralateral (the left side). (B) Summary
of the effect of nerve ligation on the number of eGFP-positive
neurons. The number was the total of eGFP-positive neurons in an
area of the SDH in an image scanned from a randomly selected
section. Open bar indicates the side contralateral to ligation (n =
18); filled bar indicates the ipsilateral side (n = 18). **P < 0.01,
significant.
Figure 4 Co-expression of PPE, GAD67 and 5-HT3 receptor
mRNAs in an eGFP-positive neuron. A neuron was subjected to
RT-PCR detection of GAD67 and 5-HT3 receptor mRNAs. Lane M
shows a 100-bp DNA ladder. Values in parentheses indicate the
expected lengths of the PCR products for NSE and GAD67, 5HT3R,
respectively.
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and intradermal injection of heat-killed Mycobacterium
butyricum to induce adjuvant arthritis [20]. In contrast
to these inflammatory forms of chronic pain induced by
various injections, there was no significant change in the
spinal cord expression of enkephalin after sciatic nerve
crush [18,26] or after complete transection of the sciatic
nerve [25].
The impact of CCI, which produces a painful neuro-
pathy of the sciatic nerve, is less clear. Quantification of
immunohistochemical staining in the spinal cord dorsal
horn showed an increase in Met-enkephalin [18,26]. On
the other hand, no significant alteration in the level of
PPE mRNA was detected by RNA blot analysis after
CCI [25]. These reports suggest that even in the same
chronic pain model, detection of enkephalin expression
levels depend on the method of analysis used. Finally, in
contrast to the results we report here, partial ligation of
the sciatic nerve has been reported to produce a non-
significant but moderate increase in enkephalin mRNA
expression, as detected by in situ hybridization [27]. A
possible explanation for these conflicting results is that
the transgenic eGFP approach taken in our study is
more sensitive than the in situ hybridization method.
Possible causes for increased number of eGFP-positive
neuron observed in sciatic nerve ligation or forskolin
treatment
There are the two explanations for the increased num-
ber of eGFP-positive neurons: elevated expression of
eGFP (and presumably enkephalin) above the detection
threshold or new expression of eGFP (and presumably
enkephalin) in populations that were previously eGFP-
negative. The increased number of eGFP-positive neu-
rons by sciatic nerve ligation or forskolin treatment may
have resulted from both mechanisms, but in either case,
it is impossible to determine which mechanism in this
study. While our data does not provide direct evidence
of a linear and homogeneous relationship between
increased eGFP and enkephalin, this issue might be
addressed in a comparison of the intensity of eGFP sig-
nal in neurons with low versus high enkephalin levels. If
the comparison shows a precise relationship between
increased eGFP and enkephalin, it might be possible to
quantify how many treatments increase the number of
enkephalinergic neurons and how much the expression
level of enkephalin in each cell is increased.
Other eGFP-transgenics used as tools in spinal dorsal
cord studies
Figure 1 shows a dense distribution of eGFP-positive
neurons in SDH. GABA-like immunoreactivity is pre-
sent in 70% of met-enkephalin-positive neurons located
in laminae II and III [13]. In transgenic mice expressing
eGFP in GABAergic neurons under the control of the
GAD67 gene (GAD1) promoter, almost every eGFP-
labeled neuron in lamina II is GABAergic [28]. In addi-
tion, more than 80% of spinal neurons expressing GFP
under the control of the prion promoter show GABA-
like immunoreactivity [29]. Our RT-PCR analysis
showed that almost all eGFP-positive neurons also
express GAD67 (Figure 4). These data suggest that a
subpopulation of eGFP-positive neurons in our study
contains GABA in SDH.
Zeilhofer et al. generated BAC transgenic mice that
express eGFP specifically in glycinergic neurons under
the control of the glycine transporter GlyT2 promoter
[ 3 0 ] .T h eB A Ct r a n s g e n i cm i c ew e r eu s e dt om e a s u r e
the change in the number of spinal glycinergic neurons
in CCI model of neuropathic pain [31]. The report sug-
gests that loss of glycinergic neurons is not necessary
for the development of pathological nociceptive behavior
in the CCI model. GABAergic neurons containing enke-
phalin do not show glycine-like immunoreactivity [13].
The mechanism underlying the loss of spinal GABAer-
gic neurons in neuropathic pain is still controversial, but
this may be due to a combination of loss of neurons
coexpressing GABA and glycine, and an increase in neu-
rons coexpressing GABA and enkephalin.
Conclusion
In conclusion, we generated BAC transgenic mice
expressing eGFP in enkephalinergic neurons. These
mice appear to be a feasible option for identifying enke-
phalinergic neurons under in vitro conditions in animal
models of persistent pain (i.e., forskolin and sciatic
nerve ligation). In addition, if eGFP is shown to have a
linear relationship with enkephalin levels, this transgenic
mouse may prove useful as an assay of enkephalin
expression levels under various conditions both in vitro
and in vivo. The physiological characterization of SDH
neurons identified as enkephalinergic neurons would
help elucidate the neuronal mechanisms underlying
nociceptive modulation in the spinal dorsal horn.
Methods
Generation of penk1-eGFP BAC transgenic mice
To visualize enkephalin-containing neurons, we gener-
ated BAC transgenic mice expressing eGFP in enkepha-
linergic neurons under the control of the penk1
promoter. A BAC containing the penk1 gene was used
to generate penk1-eGFP BAC transgenic mice. The
eGFP gene was inserted after the ATG start codon of
the penk1 gene. Transgenic mice expressing eGFP under
the control of a BAC DNA containing the enkephalin
gene were produced. BAC in Escherichia coli (E. coli)
were modified based on a protocol developed by Yang
et al. [32]. In the targeting construct, the eGFP cDNA
Fukushima et al. BMC Neuroscience 2011, 12:36
http://www.biomedcentral.com/1471-2202/12/36
Page 5 of 9was inserted in front of the stop codon of the penk1
gene, generating a C-terminal fusion protein. The
recombinant cassette was introduced into pBluescript II
KS (Stratagene), which contained the open reading
frame of the eGFP gene. Fragment A (FA) consisted of
50 bp prior to the ATG site of the PPE gene, and frag-
ment B (FB) consisted of 50 bp subsequent to exon 1 of
the gene. pBluescript II KS-FA-eGFP-FB was trans-
formed into DH10B E. coli containing BAC clone RP23-
365K8 (Invitrogen, Carlsbad, CA, USA). Modified BAC
clones were produced by two homologous recombina-
tions in E. coli and confirmed by PCR analysis. The
BAC DNA was prepared using a Nucleobond BAC 100
kit (Macherey-Nagel, Düren, Germany) and was linear-
ized. Subsequently, the linearized DNA was run on a
pulsed-field gel and purified from the gel with GenePure
LE agarose (BM, Tokyo, Japan). The linearized BAC
DNA was injected into pronuclei of C57BL/6 mouse
zygotes. Genomic DNAs of founder mice were collected
from their tail blood. The founder mice were screened
by PCR for the presence of the eGFP gene and 5’-a n d
3’-ends of the linearized BAC DNA with primers 5’-
GACACGCTGAACTTGTGG-3’ and 5’-
CTGGTCCTGATCCACGAC-3’. The founder mice
were bred with wild-type C57BL/6 mice (Japan SLC,
Shizuoka, Japan), F1 mice were subsequently crossed
with each other, and then transgenic lines were main-
tained by sibling mating. In this study, these transgenic
mice are referred to as penk1-eGFP BAC transgenic
mice.
All animal experiments were approved by the institu-
tional animal care and use committees at the Dokkyo
M e d i c a lU n i v e r s i t y .T h ec a r ea n du s eo ft h ea n i m a l s
were in accordance with the National Institutes of
Health guidelines on animal care and the guidelines of
the International Association for the Study of Pain [33].
Preparation of spinal cord sections
Animals aged 6-8 weeks were intraperitoneally anesthe-
tized with pentobarbital (50 mg/kg) and segments of the
spinal cord at the lumbosacral (L4-S1) level were
removed. A microslicer (Dosaka EM, Osaka, Japan) was
used to cut transverse sections in ice-cold modified
Krebs solution [equilibrated with 95% O2-5% CO2,c o n -
taining (in mM) 212 sucrose, 3 KCl, 25 NaHCO3,1
NaH2PO4, 2 CaCl2,1M g S O 4,a n d1 1D - g l u c o s e ;p H
7.4]. The thickness of the sections was 350-450 μmf o r
the measurement of fluorescence intensity of eGFP and
500 μm for the immunohistochemistry experiments.
Immunohistochemical study
Transverse sections 500-μm-thick were stored in modified
Krebs solution containing colchicine (10 μg/mL; Sigma, St.
Louis, MO, USA) for 6 h at room temperature. Colchicine,
an axonal transport blocking agent, was used to enhance
the signal-to-background ratio and to clearly show the
colocalization of endogenous PPE and eGFP in SDH neu-
rons. The sections were cryoprotected in 30% sucrose/PBS
overnight at 4°C. Cryosections of 20 μmt h i c k n e s sw e r e
prepared using a cryostat, and then blocked with 5% nor-
mal goat serum in PBS containing 0.1% Triton X-100 for
1 h at room temperature. After blocking, sections were
immunostained with blocking solution containing mouse
monoclonal anti-Met- and Leu-enkephalin antibody
(1:200; Millipore, Billerica, MA, USA) and rabbit polyclo-
nal anti-eGFP antibody (1:500; MBL, Woburn, MA, USA)
overnight at 4°C. Sections were washed with PBS and then
incubated with DyLight 488-labeled goat anti-rabbit IgG
for anti-eGFP antibody and DyLight 549-labeled goat anti-
mouse IgG (1:1000; KPL, Gaithersburg, MD, USA) for
anti-enkephalin antibody for 1 h at room temperature.
Sections were rinsed in PBS, mounted in Fluoromount
(Diagnostic BioSystems, Pleasanton, CA, USA) and cover-
slipped. Sections were observed using a confocal laser
scanning microscope (FluoView FV500; Olympus, Tokyo,
Japan). The numbers of neurons immunolabeled with
both anti-enkephalin and anti-eGFP as well as with anti-
eGFP alone were counted.
Measurement of eGFP-positive neurons in sections
treated with forskolin
For these experiments and for single-neuron RT-PCR
experiments, we used a fixed-stage upright microscope
equipped with a confocal laser scanning system. Spinal
sections were perfused with Krebs solution containing
forskolin (an activator of AC; Sigma; 5 μM). To record
the time course of eGFP fluorescence intensity, images
were obtained every 5 min in the confocal laser scan-
ning microscope. The percent increase was estimated by
dividing the number of eGFP-positive neurons with for-
skolin treatment by the number of control neurons
without forskolin treatment at the same time point.
Partial ligation of the sciatic nerve
Partial ligation of the sciatic nerve was performed in
penk1-eGFP BAC transgenic mice aged 7-9 weeks. The
mice were kept at controlled room temperature under a
12 h light:dark cycle. They were anesthetized by intra-
peritoneal injection of sodium pentobarbital (50 mg/kg).
The left sciatic nerve was partially ligated according to
the protocol described by Seltzer et al. [34].
Assessment of mechanical allodynia induced by partial
ligation of the sciatic nerve
Each mouse was placed in a clear plastic box (height, 15
cm; diameter, 12 cm) on an elevated metal mesh floor.
The withdrawal threshold to mechanical stimulation was
determined. A mechanical stimulus was applied from
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foot using an Electro von Frey (Model 1601; IITC,
Woodland Hills, CA, USA). The lowest strength from
five tests that induced a withdrawal response was con-
sidered the withdrawal threshold. Measurements were
obtained on individual mice every day from 3 days prior
to surgery to 21 days after surgery.
Single-neuron RT-PCR
After incubation in modified Krebs solution for 1 h at
37°C, spinal sections were mounted in a recording
chamber on the stage of a fixed-stage upright micro-
scope (BX50WI; Olympus) and continuously perfused
with Krebs solution [equilibrated with 95% O2-5% CO2,
containing (in mM) 113 NaCl, 3 KCl, 25 NaHCO3,1
NaH2PO4, 2 CaCl2, 1 MgCl2, and 11 D-glucose; pH 7.4].
After eGFP-positive neurons were identified in SDH
using a confocal laser scanning system (FluoView 300;
Olympus), as previously described [16], neurons were
aspirated into a pipette under infrared differential inter-
ference contrast (IR-DIC) optics, and a CCD video cam-
era (IR-CCD 2400; Hamamatsu Photonics, Hamamatsu,
Japan) [10]. The collecting pipette had a tip diameter of
approximately 3.5 μm and contained 2 μLo fC a
2+-free
and Mg
2+-free PBS. The neurons were then injected
into thin-walled autoclaved PCR tubes under gentle
positive pressure and immediately frozen and stored at
-80°C until use. The PCR tubes contained 2 μLM g C l 2
(25 mM), 2 μL 10 × PCR buffer, 0.5 μLR N a s ei n h i b i t o r
(40,000 units/mL), 2 μL nonionic detergent IGEPAL
CA-630 (5%), and 5 μL diethylpyrocarbonate-treated
water. On the following day, lysis was performed using
IGEPAL CA-630 at room temperature for 5 min; the
reverse transcription (RT) mixture, containing 1 μL
oligo primers (0.5 μg/L), 2 μL mixed deoxynucleotide
triphosphates (dNTPs, 10 mM), 2 μL dithiothreitol (0.1
M), 0.5 μL RNase inhibitor (40,000 units/mL), and 1 μL
SuperScript II RT (200 units/μL), was then added. The
reaction mixture was incubated at 42°C for 50 min and
subsequently heat-inactivated at 70°C for 15 min. The
total volume of 20 μL complementary DNA (cDNA)
was stored at -20°C. PCRs were performed in 50 μLo f
solution containing 20 mM Tris-HCl, 50 mM KCl, 2.5
mM MgCl2, 0.2 mM dNTPs, and 2.5 units of Taq DNA
polymerase. The concentration of primers was 20 nM in
the first PCR and 200 nM in the second PCR. The pri-
mers targeted five genes: neuron-specific enolase (NSE),
PPE, GAD67, 5-HT3 receptor, and eGFP. The primer
sequences and product lengths are listed in Table 1.
The amount of cDNA used for the first PCR varied from
3t o7μL and 1 μL of the first PCR product was used for
the second PCR. A thermal cycler (GeneAmp 2400; Perkin
Elmer, Waltham, MA, USA) was programmed for 35-40
cycles of 1 min of denaturation (94°C), 1 min of annealing
(54-59°C), and 1 min of elongation (72°C). The second
PCR products were visualized by electrophoresis on 2%
agarose gel with ethidium bromide staining. All products
were sequenced with dye terminator chemistry (Applied
Biosystems, Foster City, CA, USA) and a DNA sequencer
(Model 377; Applied Biosystems), and matched the pub-
lished sequences. All reagents for the RT-PCR procedure,
except the RNase inhibitor (Toyobo, Osaka, Japan) and
IGEPAL CA-630 (Sigma), were obtained from Gibco/Invi-
trogen (Carlsbad, CA, USA).
Statistical analysis
Data are presented as mean ± SE unless otherwise sta-
ted. Effects of sciatic nerve ligation on the number of
eGFP-positive neurons were compared using a paired t-
test. In addition, Student’s t-test was used when appro-
priate. The data for the forskolin experiment were statis-
tically analyzed by two-way analysis of variance
(ANOVA), followed by post hoc multiple comparison
(Tukey’s test). P < 0.05 was considered significant.
List of Abbreviations
5-HT: 5-hydroxytryptamine; 5-HT3: 5-HT type 3; AC: Adenylate Cyclase; BAC:
Bacterial Artificial Chromosome; CCI: Chronic constriction injury; cAMP:
Table 1 Primers used for single-neuron reverse transcription-polymerase chain reaction (RT-PCR)
Gene Name Primer Sequences Sequence Start Product Length, bp GenBank Accession Number
PPE PPE-F 5’-CTACAGGCGCGTTCTTCTCT-3’ 273 201 NM_001002927
PPE-R 5’-AGCAGCAAACAGGATGA-3’ 561
GAD67 GAD67-F 5’-CAAGTTCTGGCTGATGTGGA-3’ 1616 231 NM_008077
GAD67-R 5’-GCCACCCTGTGTAGCTTTTC-3’ 1846
5HT3R 5HT3-F 5’-CGTCAAGTCTGGTTTCCTTACC-3’ 1794 112 NM_013561
5HT3-R 5’-GCATCTATGCAAGATGATTTGC -3 1905
PPE, preproenkephalin; GAD67, glutamate decarboxylase 67 gene; 5HT3R, 5-hydroxytryptamine (5-HT, serotonin) type 3 receptor gene. Two 5-HT3 receptor
subunits were cloned, namely subunit A (5-HT3A) and subunit B (5-HT3B). Although expression of 5-HT3A subunits alone yields functional 5-HT3 receptors, it has
been suggested that 5-HT3B subunits modify the physiological and pharmacological properties of 5-HT3 receptors [35,36]. In this study we attempted to detect
the 5-HT3A subunits. The primers were used for both the first and the second PCR amplification.
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Page 7 of 9cyclic-AMP; eGFP: Enhanced Green Fluorescent Protein; GABA: γ-
aminobutyric acid; GAD67: Glutamate Decarboxylase 67; GFP: Green
Fluorescence Protein; NSE: Neuron-Specific Enolase; PPE: Preproenkephalin;
penk1: PPE gene; RT-PCR: Reverse-Transcription Polymerase Chain Reaction;
SDH: Superficial Dorsal Horn;
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